Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 7/20 | 0.62 |
| ▸ | NPY4R | P50391 | 7/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.62 |
| ▸ | NPY1R | P25929 | 5/20 | 0.62 |
| ▸ | CALCR | P30988 | 4/20 | 0.59 |
| ▸ | EP300 | Q09472 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TFPI | P10646 | 2/20 | 0.59 |
| ▸ | F2 | P00734 | 2/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31182516 | 0.95 | NPY2R (0.64) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL29695646 | 0.92 | NPY2R (0.63) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31182495 | 0.89 | NPY2R (0.70) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30495699 | 0.89 | CALCR (0.73) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30883230 | 0.89 | RAMP3 (0.64) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL29374929 | 0.88 | APLNR (0.61) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30712966 | 0.88 | NPY2R (0.61) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31182550 | 0.88 | APLNR (0.69) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30073937 | 0.88 | F2 (0.62) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30547344 | 0.88 | EPHA2 (0.55) | NPY2RNPY4RNPY5RNPY1RCALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| US-20220119840-A1 | CLOSED-ENDED DNA (CEDNA) AND USE IN METHODS OF REDUCING GENE OR NUCLEIC ACID THERAPY RELATED IMMUNE RESPONSE | GENERATION BIO CO. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119840-A1 | CLOSED-ENDED DNA (CEDNA) AND USE IN METHODS OF REDUCING GENE OR NUCLEIC ACID THERAPY RELATED IMMUNE RESPONSE | STING1, DCLRE1B, DCLRE1A | NPY2R 4542/4885NPY4R 4597/4885NPY5R 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.